Compound: Volasertib
SMILES: O=C1N(c2c(nc(Nc3c(OC)cc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3)nc2)N([C@@H]1CC)C(C)C)C
InChIKey: SXNJFOWDRLKDSF-STROYTFGSA-N
Synonyms: Volasertib, 755038-65-4, BI 6727, Volasertib (BI 6727), BI-6727, BI6727, C34H50N8O3, Volasertib [USAN], BI6727 (Volasertib), Volasertib(BI6727), MFCD20926414, CHEMBL5276995, 6EM57086EA, Volasertib (USAN), n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide, N-(Trans-4-(4-(cyclopropylMethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-Methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)aMino)-3-MethoxybenzaMide, N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide, Bi6727(volasertib), N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide, Volasertib [USAN:INN], volasertibum, UNII-6EM57086EA, Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-, BENZAMIDE, N-[TRANS-4-[4-(CYCLOPROPYLMETHYL)-1-PIPERAZINYL]CYCLOHEXYL]-4-[[(7R)-7-ETHYL-5,6,7,8-TETRAHYDRO-5-METHYL-8-(1-METHYLETHYL)-6-OXO-2-PTERIDINYL]AMINO]-3-METHOXY-, BI 6727; N-[trans-4-[4-(Cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, IBI, N-[trans-4-[4-(Cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl]amino]-3-methoxybenzamide, BI6727,Volasertib, VOLASERTIB [INN], VOLASERTIB [WHO-DD], MLS006011195, SCHEMBL738946, GTPL7947, orb1301146, SCHEMBL2169101, SCHEMBL9888052, CHEMBL1233528, CHEMBL4284151, SCHEMBL21916558, SCHEMBL29363620, SCHEMBL30753526, CHEBI:231358, DTXSID801099395, DTXSID901025694, GLXC-90219, EX-A1364, FFB03865, BDBM50402023, BDBM50613682, NSC757149, NSC800965, s2235, AKOS005266487, AKOS030257530, CCG-264952, CS-0274, DB12062, NSC-757149, NSC-800965, SDCCGSBI-0654409.P001, NCGC00263087-01, NCGC00263087-02, NCGC00263087-03, NCGC00263087-11, NCGC00263087-12, NCGC00263087-14, NCGC00263087-15, NCGC00485964-01, AC-32844, AS-16996, HY-12137, N-((1s,4S)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide, SMR004702964, SY122287, NS00073642, SW218140-2, D10182, SR-03000003275, Q7939986, SR-03000003275-1, BRD-K69776681-001-03-8, BRD-K69776681-001-06-1, 755038-54-1, N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide, N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-benzamide, N-[cis-4-[4-(Cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide, N-{(1r,4R)-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}-4-{[(7R)-7-ethyl-5-methyl-6-oxo-8-(propan-2-yl)-5,6,7,8-tetrahydropteridin-2-yl]amino}-3-methoxybenzamide
Theoretical properties:
molecular_formula: C34H50N8O3
molecular_weight: 618.8 g/mol
exact_mass: 618.40058749 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 9
rotatable_bond_count: 10
heavy_atom_count: 45
topological_polar_surface_area: 106 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Volasertib is a member of the class of pteridines that is (7R)-7-ethyl-5-methyl-8-(propan-2-yl)-7,8-dihydropteridin-6(5H)-one substituted by a [4-({trans-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}carbamoyl)-2-methoxyphenyl]amino group at position 2. It is as polo-like kinase 1 inhibitor (IC50 = 0.87 nM) with potential antineoplastic activity. It has a role as an EC 2.7.11.21 (polo kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a secondary carboxamide, a member of benzamides, a monomethoxybenzene, a member of piperazines, a member of pteridines, a substituted aniline, a secondary amino compound, a tertiary amino compound and a member of cyclopropanes.
chebi: A member of the class of pteridines that is (7<i>R</i>)-7-ethyl-5-methyl-8-(propan-2-yl)-7,8-dihydropteridin-6(5<em>H</em>)-one substituted by a [4-({<i>trans</i>-4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl}carbamoyl)-2-methoxyphenyl]amino group at position 2. It is as polo-like kinase 1 inhibitor (IC<small><sub>50</sub></small> = 0.87 nM) with potential antineoplastic activity.
chembl: VOLASERTIB is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.
Volasertib was awarded breakthrough drug status in September 2013 and orphan drug status for acute myeloid leukemia in April 2014.